BioNTech SE (BNTX) Misses Q2 EPS by 134c, reiterates guidance

Go back to BioNTech SE (BNTX) Misses Q2 EPS by 134c, reiterates guidance

BioNTech (BNTX) PT Lowered to $93 at Morgan Stanley

August 5, 2024 2:32 PM EDT

Morgan Stanley analyst Terence Flynn lowered the price target on BioNTech (NASDAQ: BNTX) to $93.00 (from $101.00) while maintaining a Equalweight rating.

The analyst comments "BNTX reported a beat on revs but a miss on the bottom line due to higher OpEx. 2024 guidance was reiterated. Upcoming... More